Research progress of dual inhibitors targeting HIV-1 reverse transcriptase and integrase.
- Author:
Hong LIU
1
;
Peng ZHAN
;
Xin-Yong LIU
Author Information
1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmacy, Shandong University, Ji 'nan 250012, China.
- Publication Type:Journal Article
- MeSH:
Drug Design;
HIV Integrase Inhibitors;
chemistry;
pharmacology;
HIV Reverse Transcriptase;
antagonists & inhibitors;
HIV-1;
drug effects;
Humans;
Molecular Structure;
Reverse Transcriptase Inhibitors;
chemistry;
pharmacology;
Structure-Activity Relationship
- From:
Acta Pharmaceutica Sinica
2013;48(4):466-476
- CountryChina
- Language:Chinese
-
Abstract:
Both reverse transcriptase (RT) and integrase (IN) play crucial roles in the life cycle of HIV-1, which are also key targets in the area of anti-HIV drug research. Reverse transcriptase inhibitors are involved in the most employed drugs used to treat AIDS patients and HIV-infected people, while one of the integrase inhibitors has already been approved by US FDA to appear on the market. Great achievement has been made in the research on both, separately. Recently, much more attention of medicinal chemistry researchers has been attracted to the strategies of multi-target drugs. Compounds with excellent potency against both HIV RT and IN, evidently defined as dual inhibitors targeting both enzymes, have been obtained through considerable significant exploration, which can be classified into two categories according to different strategies. Combinatorial chemistry approach together with high throughput screening methods and multi-target-based virtual screening strategy have been useful tools for identifying selective anti-HIV compounds for long times; Rational drug design based on pharmacophore combination has also led to remarkable results. In this paper, latest progress of both categories in the discovery and structural modification will be covered, with a view to contribute to the career of anti-HIV research.
